LEO Pharma Pays $727 Million for Astellas' Global Dermatology Products

LEO Pharma A/S, a global dermatological company based in Denmark, paid $727 million to acquire global rights to the dermatology assets of Japan's Astellas Pharma. LEO said the acquisition, which is the largest transaction in its 100-year history, will add 20% to revenues. Among other benefits, the acquisition will increase LEO's presence in China and Russia. Before the transaction, LEO was already the largest MNC focused exclusively on dermatology products in China and number four in derm products overall. More details.... Share this with colleagues: // //